Transfusion Medicine - Prevention of Bedside Errors

This study has been completed.
Sponsor:
Collaborator:
BEST research collaborative
Information provided by:
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT00127556
First received: August 4, 2005
Last updated: May 6, 2008
Last verified: May 2008
  Purpose

This study concerns the safety of blood transfusion. Prior to transfusion, staff should perform a number of essential safety checks to ensure that the correct patient is receiving the correct blood product. Evidence suggests that these safety checks are not always done. This study has been designed to assess the effect of a simple intervention on the performance of the bedside safety check.

The hypothesis is that a simple intervention will improve the performance of the bedside check.


Condition Intervention
Blood Transfusion
Procedure: Label applied to blood bag

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Factorial Assignment
Masking: Open Label
Official Title: Cluster-Randomised Controlled Trial of a Simple Intervention to Prevent Bedside Checking Errors in Blood Transfusion

Resource links provided by NLM:


Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • The primary endpoint is one proportion combining the 3 elements of the bedside check, that is: the proportion of transfusions in which the staff ask the patient to state his/her surname and first name and check that they are the same on the wristband
  • the proportion of transfusions in which the staff check to see that the patient's surname, first name and hospital number are the same on the wristband and on the label attached to the unit by the blood bank
  • the proportion of transfusions in which the staff check to see that the unit number is the same on the blood bag and on the label attached to the unit by the blood bank.

Estimated Enrollment: 300
Study Start Date: April 2005
Study Completion Date: December 2005
Detailed Description:

The local collaborator at each participating hospital will identify two clinical areas comparable for the following elements: similar hours of service, similar use of red cells, similar level of intensity, and similar nurse-to-patient staffing ratios. For the purposes of this study, a clinical area is defined as a discrete area where one type of clinical care takes place. Comparability will be established by completion of a checklist.

The local collaborator will transmit comparability data to the study co-ordinator who will pass it on to a nominated medical consultant (Professor Mike Murphy) and the study statistician. If both parties are satisfied that the two clinical areas are comparable, confirmation will be transmitted to the local collaborator together with authority to commence the two-week baseline audit. Once the baseline is complete the local collaborator will contact the statistician, via the co-ordinator, to be informed of the area for intervention. The local collaborator will then inform the blood bank of the intervention area.

The intervention will be applied to one clinical area or ward in each participating hospital. Both clinical areas will be audited during a two-week baseline observation period. The two areas will then be randomly allocated to either the intervention of labeled blood bags or no intervention. Auditing will carry on in both areas until 2 weeks after the intervention has been introduced. To assess the longer-term impact of the intervention, there will be a further two-week period of audit 8 weeks from the start of the intervention. The intervention will be carried out for the full 10-week period.

The randomized comparison will be based on the data collected in the 2-week period after one area has received the labeled bags, and both areas have been observed by an observer for the same length of time. Thus the effect of the intervention will be separated from any initial effect that the observer may have on bedside checking practice. This comparison will also be made on the long-term audit data collected at 8-weeks.

The intervention under investigation is a simple label applied to the blood bag in such a way to cover (obstruct entry) the "ports" used to administer blood. The label will be applied to units of crossmatched red cells only. The position of the label will require that the user remove the label to administer the red cells. The label will state: "STOP: Check the patient's wristband". The wording will be translated to the appropriate language as necessary.

Observers (auditors)- not blinded to the test or control areas - will be asked to audit the bedside check at the time of transfusion. This will be done by direct observation. The auditor will take up a position to observe practice and will therefore be obvious to the staff. However the auditor will not participate in the transfusion check, not answer questions, and not reveal observed errors in the check (unless they observe that the wrong blood will be transfused, in which case they should intervene). Observations will be recorded on the data form.

Participants are invited from Europe, North America, South America, Asia and Australia. The target is for at least 15 hospitals.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Crossmatched red cells

Exclusion Criteria:

  • Uncrossmatched red cells, platelets, fresh frozen plasma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00127556

Locations
United States, California
LA County and USC Medical Centre
Los Angeles, California, United States, 90033
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114-2696
Beth Israel Deaconess Medical Centre
Boston, Massachusetts, United States, 02215
United States, New Hampshire
Dartmouth-Hitchcock Medical Centre
Lebanon, New Hampshire, United States, 03756
United States, Ohio
Cincinnati Children's Hospital Medical Centre
Cincinnati, Ohio, United States, 45267
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44106
Australia, New South Wales
Royal North Shore Hospital
St Leonards, New South Wales, Australia, 2065
Brazil
Hospital Sirio Libanes Blood Bank
Sao Paulo, Brazil, 01308-050
Canada, Ontario
Hamilton Health Sciences
Hamilton, Ontario, Canada, L8N 3Z5
Sunnybrook & Women's Hospital
Toronto, Ontario, Canada, M4N 3M5
Norway
Haukeland University Hospital
Bergen, Norway, N-5021
United Kingdom
Great Ormond Street
London, United Kingdom
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
BEST research collaborative
Investigators
Principal Investigator: Walter Dzik, MD Massachusetts General Hospital, USA
Principal Investigator: Mike F Murphy, FRCPath, MD National Blood Service, England
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00127556     History of Changes
Other Study ID Numbers: TM-PROBE study
Study First Received: August 4, 2005
Last Updated: May 6, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Dartmouth-Hitchcock Medical Center:
Transfusion
Safety

ClinicalTrials.gov processed this record on August 19, 2014